Re-emergence of yellow fever in Brazil during 2016–2019: challenges, lessons learned, and perspectives

P de Oliveira Figueiredo, AG Stoffella-Dutra… - Viruses, 2020 - mdpi.com
Yellow fever (YF) is a re-emerging viral zoonosis caused by the Yellow Fever virus (YFV),
affecting humans and non-human primates (NHP). YF is endemic in South America and …

[HTML][HTML] Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials

CC Lai, CM Chao, PR Hsueh - Journal of Microbiology, Immunology and …, 2021 - Elsevier
Despite aggressive efforts on containment measures for the coronavirus disease 2019
(COVID-19) pandemic around the world, severe acute respiratory syndrome coronavirus 2 …

Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production

N Fintelman-Rodrigues, CQ Sacramento… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for
far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The …

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19) …

A Sadeghi, A Ali Asgari, A Norouzi… - Journal of …, 2020 - academic.oup.com
Background Currently no effective antiviral therapy has been found to treat COVID-19. The
aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical …

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with …

H Abbaspour Kasgari, S Moradi… - Journal of …, 2020 - academic.oup.com
Background New therapeutic options are urgently needed to tackle the novel coronavirus
disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate …

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

CQ Sacramento, N Fintelman-Rodrigues… - Journal of …, 2021 - academic.oup.com
Background Current approaches of drug repurposing against COVID-19 have not proven
overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global …

Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial?

B Sayad, M Sobhani, R Khodarahmi - Archives of medical research, 2020 - Elsevier
COVID-19 is a devastating global pandemic around the world. While the majority of infected
cases appear mild, in some cases individuals present respiratory complications with …

Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication

AC Ferreira, PA Reis, CS de Freitas… - Antimicrobial agents …, 2019 - Am Soc Microbiol
Chikungunya virus (CHIKV) causes a febrile disease associated with chronic arthralgia,
which may progress to neurological impairment. Chikungunya fever (CF) is an ongoing …

A critical assessment of mosquito control and the influence of climate change on mosquito-borne disease epidemics

AN Anoopkumar, EM Aneesh - Environment, Development and …, 2022 - Springer
The world has experienced perceptible climate change for the past 100 years. Global
warming enhances the rapid spread of mosquito-borne diseases resulting in unknown …

Therapeutics for flaviviral infections

AM Bifani, KWK Chan, D Borrenberghs, MJA Tan… - Antiviral Research, 2023 - Elsevier
Flaviviruses are vector-borne pathogens capable of causing devastating human diseases.
The re-emergence of Zika in 2016 notoriously led to a widescale epidemic in the Americas …